{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:58:21Z","timestamp":1792533501156,"version":"4.5.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with resectable esophageal squamous cell carcinoma (ESCC) receiving neoadjuvant immunotherapy (NIT) display variable treatment responses. The purpose of this study is to establish and validate a radiomics based on enhanced computed tomography (CT) and combined with clinical data to predict the major pathological response to NIT in ESCC patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study included 82 ESCC patients who were randomly divided into the training group (n = 57) and the validation group (n = 25). Radiomic features were derived from the tumor region in enhanced CT images obtained before treatment. After feature reduction and screening, radiomics was established. Logistic regression analysis was conducted to select clinical variables. The predictive model integrating radiomics and clinical data was constructed and presented as a nomogram. Area under curve (AUC) was applied to evaluate the predictive ability of the models, and decision curve analysis (DCA) and calibration curves were performed to test the application of the models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One clinical data (radiotherapy) and 10 radiomic features were identified and applied for the predictive model. The radiomics integrated with clinical data could achieve excellent predictive performance, with AUC values of 0.93 (95% CI 0.87\u20130.99) and 0.85 (95% CI 0.69\u20131.00) in the training group and the validation group, respectively. DCA and calibration curves demonstrated a good clinical feasibility and utility of this model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Enhanced CT image-based radiomics could predict the response of ESCC patients to NIT with high accuracy and robustness. The developed predictive model offers a valuable tool for assessing treatment efficacy prior to initiating therapy, thus providing individualized treatment regimens for patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1405146","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T05:12:21Z","timestamp":1718341941000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["A machine learning radiomics based on enhanced computed tomography to predict neoadjuvant immunotherapy for resectable esophageal squamous cell carcinoma"],"prefix":"10.3389","volume":"15","author":[{"given":"Jia-Ling","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian-Sha","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jie","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12087","article-title":"Clinical characteristics and survival of 5283 esophageal cancer patients: A multicenter study from eighteen hospitals across six regions in China","volume":"40","author":"He","year":"2020","journal-title":"Cancer Commun (Lond)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr433","article-title":"Esophageal carcinoma advances in treatment results for locally advanced disease: review","volume":"23","author":"Herskovic","year":"2012","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.1483","article-title":"Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): A phase III multicenter, randomized, open-label clinical trial","volume":"36","author":"Yang","year":"2018","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1051841","article-title":"Neoadjuvant immunotherapy for resectable esophageal cancer: A review","volume":"13","author":"Li","year":"2022","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jtcvs.2023.08.056","article-title":"Two-year outcomes of clinical N2\u20133 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study","volume":"167","author":"Yang","year":"2024","journal-title":"J Thorac Cardiovasc surgery"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01888","article-title":"Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer","volume":"38","author":"Kojima","year":"2020","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-2593","article-title":"Intratumoral microbiota composition regulates chemoimmunotherapy response in esophageal squamous cell carcinoma","volume":"83","author":"Wu","year":"2023","journal-title":"Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0333-6","article-title":"Whole-genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma","volume":"30","author":"Cui","year":"2020","journal-title":"Cell Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv489","article-title":"Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies","volume":"27","author":"Ilie","year":"2016","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer","volume":"2","author":"McLaughlin","year":"2016","journal-title":"JAMA Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.6870","article-title":"Pseudoprogression and immune-related response in solid tumors","volume":"33","author":"Chiou","year":"2015","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1148\/radiol.210518","article-title":"Emerging and evolving concepts in cancer immunotherapy imaging","volume":"306","author":"Dercle","year":"2023","journal-title":"Radiology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41416-023-02547-w","article-title":"Prediction of response to neoadjuvant chemo-immunotherapy in patients with esophageal squamous cell carcinoma by a rapid breath test","volume":"130","author":"Huang","year":"2024","journal-title":"Br J cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.11.036","article-title":"Radiomics: extracting more information from medical images using advanced feature analysis","volume":"48","author":"Lambin","year":"2012","journal-title":"Eur J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1115291","article-title":"Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"6235","DOI":"10.3390\/cancers14246235","article-title":"Quantitative diffusion-weighted imaging analyses to predict response to neoadjuvant immunotherapy in patients with locally advanced head and neck carcinoma","volume":"14","author":"van der Hulst","year":"2022","journal-title":"Cancers"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-023-06394-y","article-title":"[18F]FDG PET\/CT for predicting triple-negative breast cancer outcomes after neoadjuvant chemotherapy with or without pembrolizumab","volume":"50","author":"Seban","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05610-x","article-title":"[(18)F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma","volume":"49","author":"Vos","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2439","article-title":"Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma","volume":"24","author":"Huang","year":"2018","journal-title":"Clin Cancer research: an Off J Am Assoc Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet (London England)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"106680","DOI":"10.1016\/j.ijsu.2022.106680","article-title":"Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)","volume":"103","author":"Yan","year":"2022","journal-title":"Int J Surg"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e005830","DOI":"10.1136\/jitc-2022-005830","article-title":"Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial","volume":"11","author":"Chen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"New Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01962-5","article-title":"Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial","volume":"28","author":"Chaft","year":"2022","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e003497","DOI":"10.1136\/jitc-2021-003497","article-title":"Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma","volume":"10","author":"Yang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.ccell.2023.09.011","article-title":"Progenitor-like exhausted SPRY1(+)CD8(+) T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"key":"B29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12929-023-00912-8","article-title":"PES1 reduces CD8(+) T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma","volume":"30","author":"Ma","year":"2023","journal-title":"J Biomed science"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e007847","DOI":"10.1136\/jitc-2023-007847","article-title":"High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy","volume":"11","author":"Han","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/annonc\/mdz108","article-title":"Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers","volume":"30","author":"Trebeschi","year":"2019","journal-title":"Ann oncology: Off J Eur Soc Med Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.12111607","article-title":"Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data\u2013methods and preliminary results","volume":"264","author":"Gevaert","year":"2012","journal-title":"Radiology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s00330-015-3814-0","article-title":"CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer","volume":"26","author":"Rizzo","year":"2016","journal-title":"Eur Radiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-019-06193-w","article-title":"Prediction of response after chemoradiation for esophageal cancer using a combination of dosimetry and CT radiomics","volume":"29","author":"Jin","year":"2019","journal-title":"Eur Radiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrz027","article-title":"CT-based radiomic signatures for prediction of pathologic complete response in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy","volume":"60","author":"Yang","year":"2019","journal-title":"J Radiat Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.05.023","article-title":"Sub-region based radiomics analysis for survival prediction in oesophageal tumours treated by definitive concurrent chemoradiotherapy","volume":"44","author":"Xie","year":"2019","journal-title":"EBioMedicine"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01398","article-title":"Development and validation of a radiomics nomogram model for predicting postoperative recurrence in patients with esophageal squamous cell cancer who achieved pCR after neoadjuvant chemoradiotherapy followed by surgery","volume":"10","author":"Qiu","year":"2020","journal-title":"Front Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40364-023-00480-x","article-title":"Model integrating CT-based radiomics and genomics for survival prediction in esophageal cancer patients receiving definitive chemoradiotherapy","volume":"11","author":"Cui","year":"2023","journal-title":"biomark Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1177\/2050640615601603","article-title":"CT texture analysis in colorectal liver metastases: A better way than size and volume measurements to assess response to chemotherapy","volume":"4","author":"Rao","year":"2016","journal-title":"United Eur Gastroenterol J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000441","article-title":"The gap before real clinical application of imaging-based machine-learning and radiomic models for chemoradiation outcome prediction in esophageal cancer: a systematic review and meta-analysis","volume":"109","author":"Yang","year":"2023","journal-title":"Int J Surg"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-14352-z","article-title":"Potential predictive immune and metabolic biomarkers of tumor microenvironment regarding pathological and clinical response in esophageal cancer after neoadjuvant chemoradiotherapy: A systematic review","volume":"31","author":"Wang","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.984816","article-title":"Multi-omics profiling and digital image analysis reveal the potential prognostic and immunotherapeutic properties of CD93 in stomach adenocarcinoma","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1117448","article-title":"Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"106767","DOI":"10.1016\/j.ijsu.2022.106767","article-title":"Efficacy and safety of neoadjuvant immunotherapy in surgically resectable esophageal cancer: A systematic review and meta-analysis","volume":"104","author":"Wang","year":"2022","journal-title":"Int J Surg"},{"key":"B45","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00782-x","article-title":"Emerging evidence for adapting radiotherapy to immunotherapy","volume":"20","author":"Galluzzi","year":"2023","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1405146\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T05:12:24Z","timestamp":1718341944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1405146\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2024.1405146"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1405146","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]},"article-number":"1405146"}}